<DOC>
	<DOCNO>NCT01829464</DOCNO>
	<brief_summary>The purpose study evaluate effect TAK-875 ( fasiglifam ) combination sitagliptin glycemic control adult type 2 diabetes .</brief_summary>
	<brief_title>TAK-875 ( Fasiglifam ) Combination With Sitagliptin Adults With Type 2 Diabetes</brief_title>
	<detailed_description>The drug test study call TAK-875 ( fasiglifam ) . Fasiglifam test treat people type 2 diabetes mellitus currently take sitagliptin ( without metformin ) . This study evaluate glycemic control people take fasiglifam plus sitagliptin compare placebo plus sitagliptin . The study enroll approximately 390 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ; participant 100 mg sitagliptin may may metformin background treatment ) : - fasiglifam 25 mg - fasiglifam 50 mg - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient All participants ask take one tablet time day throughout study . This multi-centre trial conduct North America Latin America . The overall time participate study approximately 38 week . Participants make 15 visit clinic . Due potential concern liver safety , balance , benefit treat patient fasiglifam ( TAK-875 ) outweigh potential risk . For reason , Takeda decide voluntarily terminate development activity fasiglifam .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant male female age 18 year old historical diagnosis T2DM . 4 . The participant meet one follow criterion : The participant HbA1c 7.5 % 10.5 % , inclusive take stable dose sitagliptin 100 mg least 8 week , without metformin , prior Screening Visit . A participant take metformin must receive stable daily dose ( ≥1500 mg document maximum tolerated dose [ MTD ] ) least 8 week Screening . This participant enter 2week singleblind Placebo RunIn Period accord Study Schedule A , ; The participant HbA1c 7.5 % 10.5 % , inclusive take DPPIV inhibitor ( without metformin ) least 8 week prior Screening Visit . A participant take metformin must receive stable daily dose ( ≥1500 mg document MTD ) least 8 week Screening . This participant enter 8week Switching Period accord Study Schedule B . Following 8week period , participant must qualify Inclusion/Exclusion Criteria prior enter 2Week Placebo Runin Period complete Week ( 3 ) procedure include HbA1c level 7.5 % 10.5 % . Note : An enrollment cap may apply ensure approximately 20 % randomized participant receive DPPIV inhibitor without metformin baseline . 5 . The participant treatment antidiabetic agent DPPIV inhibitor metformin within 2 month prior Screening ( Exception : participant receive antidiabetic therapy ≤7 consecutive day within 2 month prior Screening ) . 6 . The participant body mass index ( BMI ) ≤45 kg/m2 Screening . 7 . Participants regularly use , nonexcluded medication must stable dose least 4 week prior screen . However , PRN ( need ) use prescription overthecounter medication allow discretion investigator . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 30 day last dose study drug . 9 . The participant able willing monitor glucose home glucose monitor consistently record blood glucose concentration complete participant diary . 1 . Has receive investigational compound within 30 day prior Screening receive investigational antidiabetic drug within 3 month prior Screening . 2 . Has randomize previous TAK875 study . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ; biological legally adopt ) may consent duress . 4 . Donated receive blood product within 12 week prior Screening plan donate blood study . 5 . Has hemoglobin ≤12 g/dL ( ≤120 gm/L ) males ≤10 g/dL ( ≤100 gm/L ) females Screening Visit . 6 . Has systolic blood pressure ≥160 mm Hg diastolic pressure ≥95 mm Hg Screening ( If participant meet exclusion criterion , assessment may repeat least 30 minute initial measurement decision make base second measurement ) . 7 . Has history cancer remission &lt; 5 year prior Screening . ( Exception : A history basal cell carcinoma stage 1 squamous cell carcinoma skin allow . ) 8 . Has alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level &gt; 2.0x upper limit normal ( ULN ) Screening . 9 . Has total bilirubin level great ULN Screening . Exception : participant document Gilbert 's Syndrome , allow elevated bilirubin level per investigator 's discretion . 10 . Has serum creatinine ≥1.5 mg/dL ( ≥133 μmol/L ) [ male ] ≥1.4 mg/dL ( ≥124 μmol/L ) [ female ] and/or estimate glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m^2 Screening . 11 . Has uncontrolled thyroid disease . 12 . Has history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 13 . Has gastric band gastric bypass surgery within one year prior Screening . 14 . Has know history infection human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) . 15 . Had coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal electrocardiogram ( ECG ) , cerebrovascular accident transient ischemic attack within 3 month prior Screening . 16 . Has history pancreatitis . 17 . Has history hypersensitivity , allergies anaphylactic reaction ( ) component TAK875 well sitagliptin . 18 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening . 19 . Received excluded medication prior Screening Visit expect receive exclude medication . 20 . If female , pregnant ( confirmed laboratory testing , ie , serum/urine human chorionic gonadotropin ( hCG ) , females childbearing potential ) lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 21 . Is unable understand verbal write English language certify translation approve informed consent available . 22 . Has physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow participant accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>